Bozeman, MT – According to filings with the U.S. Securities and Exchange Commission, Microbion is raising $13,390,627.00 in new funding. Sources indicate as part of senior management President, Brett Baker played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Microbion
Microbion is a clinical-stage pharmaceutical company developing a novel class of compounds for the treatment of difficult-to-treat infections, including chronic infections and antibiotic-resistant infections, who is dedicated to developing best-in-class, novel medicines that addresses key unmet medical needs improve the lives of patients. Microbions lead drug candidate, pravibismane, the first in a new class of anti-infectives that inhibits microbial cellular metabolism, is in Phase 2 clinical development for topical/local treatment of diabetic foot ulcer infection and orthopedic device related infection. Results from early-stage clinical studies indicated that the drug was well tolerated and showed promise to improve treatment outcomes in these patients. In addition, an inhalation formulation of pravibismane is pre-clinical development for the treatment of chronic lung infections. The inhalation program is supported by funding from CARB-X and the CF Foundation up to a total of $17.1 million through to Phase 1b. Microbion has been granted QIDP and Fast Track designations for all indications in development and Orphan Drug Designation for the treatment (management) of pulmonary infections in patients with cystic fibrosis by the US FDA. Pravibismane has anti-infective efficacy against a broad spectrum of pathogens, including Gram -positive and -negative bacterial and fungal species, and multiple resistant priority pathogens or superbugs identified by the US CDC. Furthermore, pravibismane has also demonstrated the ability to eradicate microbial biofilms. Microbions site specific delivery approach avoids systemic administration of our compounds that potentially: enables higher therapeutic concentration of drug at site of infection resulting in greater efficacy; reduces off-target effects and toxicity resulting in an improved safety profile; and lowers risk of developing antibiotic resistance that is associated with systemic antibiotic administration.

To learn more about Microbion, visit http://www.microbioncorp.com/

Contact:
Brett Baker, President
406-233-6472
https://www.linkedin.com/in/brett-baker-605a951/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved